Proton pump inhibitors and fracture risk: True effect or residual confounding?

Drug Safety

Volumn 33, Issue 10, 2010, Pages 843-852

  Bodmer, Michael ^a,b   Meier, Christian ^a   Kraenzlin, Marius E ^a   Meier, Christoph R ^a,c,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^c UNIVERSITY OF BASEL   (Switzerland)

^d BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone disorders, drug induced; Calcium metabolism; Fracture, drug induced; Histamine H2 receptor antagonists, adverse reactions; Proton pump inhibitors, adverse reactions

Indexed keywords

CALCIUM CARBONATE; ESOMEPRAZOLE; HISTAMINE H3 RECEPTOR ANTAGONIST; HOMOCYSTEINE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

BONE METABOLISM; CALCIUM ABSORPTION; CYANOCOBALAMIN DEFICIENCY; EMBASE; FRACTURE; HUMAN; HYPERHOMOCYSTEINEMIA; MEDLINE; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

AGED; BONE AND BONES; CALCIUM; FRACTURES, BONE; HUMANS; PROTON PUMP INHIBITORS; RISK;

EID: 77956300048     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11536780-000000000-00000     Document Type: Review

References (36)

1. Soderqvist A, Ekstrom W, Ponzer S, et al. Prediction of mortality in elderly patients with hip fractures: a two-year prospective study of 1,944 patients. Gerontology 2009; 55 (5): 496-504
2. Vestergaard P, Rejnmark L, Mosekilde L.Has mortality after a hip fracture increased? JAmGeriatr Soc 2007; 55 (11): 1720-1726
3. Bodmer M, Meier C, Kraenzlin ME, et al. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009; 32 (7): 539-547
4. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch InternMed 2008; 168 (8): 820-825
5. Corley DA, Kubo A, ZhaoW, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139 (1): 93-101
6. de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20 (12): 1989-1998
7. de Vries F, van Staa TP, Leufkens HGM, et al. Use of proton pump inhibitors and risk of hip fracture. EULAR 2009 Jun 10-13. Copenhagen
8. Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas 2009; 64 (1): 9-13
9. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Womens Health Initiative. Arch Intern Med 2010; 170 (9): 765-71
10. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179 (4): 319-326
11. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79 (2): 76-83
12. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296 (24): 2947-2953
13. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009; 84 (1): 13-19
14. Ali T, Lam D, Bronze MS, et al. Osteoporosis in inflammatory bowel disease. Am J Med 2009; 122 (7): 599-604
15. Cashman KD. Diet, nutrition, and bone health. J Nutr 2007; 137 (11 Suppl.): 2507-12S
16. Reid IR, Bolland MJ, Grey A. Effect of calcium supplementation on hip fractures. Osteoporos Int 2008; 19 (8): 1119-1123
17. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitaminDsupplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370 (9588): 657-666
18. Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 2007; 22 (3): 286-296
19. Wood RJ, Serfaty-Lacrosniere C. Gastric acidity, atrophic gastritis, and calcium absorption.NutrRev 1992; 50 (2): 33-40
20. Goerss JB, Kim CH, Atkinson EJ, et al. Risk of fractures in patients with pernicious anemia. J BoneMiner Res 1992; 7 (5): 573-579
21. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009; 104 Suppl. 2: S2-4
22. Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53 (1): 21-25
23. Adachi Y, Shiota E, Matsumata T, et al. Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int 1998; 62 (4): 283-285
24. Graziani G, Badalamenti S, Como G, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload: role of gastric acid secretion. Nephron 2002; 91 (3): 474-479
25. Hardy P, Sechet A, Hottelart C, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 1998; 22 (7): 569-573
26. Graziani G, Como G, Badalamenti S, et al.Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects.NephrolDial Transplant 1995; 10 (8): 1376-1380
27. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995; 14 (4): 364-368
28. OConnell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118 (7): 778-781
29. Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984; 73 (3): 640-647
30. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138 (3): 896-904
31. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57 (4): 422-428
32. McLean RR, Jacques PF, Selhub J, et al. Plasma B vitamins, homocysteine, and their relation with bone loss and hip fracture in elderly men and women. J Clin Endocrinol Metab 2008; 93 (6): 2206-2212
33. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350 (20): 2042-2049
34. Roblin X, Phelip JM, Genevois M, et al. Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohns disease. Aliment Pharmacol Ther 2007; 25 (7): 797-804
35. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28 (8): 951-959
36. Leslie WD, Anderson WA, Metge CJ, et al. Clinical risk factors for fracture in postmenopausal Canadian women: a population-based prevalence study. Bone 2007; 40 (4): 991-996